SRPT - Sarepta Therapeutics Inc.
收市後：
| 前收市價 | 126.17 |
| 開市 | 127.69 |
| 買盤 | 0.00 x 1400 |
| 賣出價 | 0.00 x 900 |
| 今日波幅 | 126.05 - 130.32 |
| 52 週波幅 | 61.28 - 159.89 |
| 成交量 | |
| 平均成交量 | 1,633,092 |
| 市值 | 11.979B |
| Beta 值 (5 年，每月) | 1.02 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -12.88 |
| 業績公佈日 | 2023年7月31日 - 2023年8月04日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 173.74 |
Insider Monkey15 Best Healthcare Stocks To Buy Now
In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]
BenzingaFDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks
The FDA informed Sarepta Therapeutics Inc (NASDAQ: SRPT) that it requires modest additional time to complete the review of its SRP-9001 (delandistrogene moxeparvovec) for Duchenne muscular, including final label negotiations and postmarketing commitment discussions. Last week, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta's SRP-9001. The agency has extended the review date from May 29 to June 22. Following discuss
BenzingaFDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene moxeparvovec) for ambulatory patients with Duchenne muscular dystrophy. The FDA is slated to make a decision on accelerated approval by May 29. The agency typically follows the advice of its expert advisers but is not obligated to do so. "Today's advisory committee outcome is extremely important to
Insider MonkeySarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Call Transcript May 2, 2023 Operator: Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2023 Earnings Call. At this time all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. As a reminder, today’s program is being recorded. At […]
BenzingaAccelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood pressure, which are characteristics of the body that can be measured. The FDA will support using biomarkers as substitutes for other biological indicators in gene-therapy clinical trials to help clinch "accelerated approval," Reuters reported citing the agency's official Peter Marks. FDA grants acceler
- Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
https://cdn.benzinga.com/files/images/story/2023/03/17/srpt.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 The FDA will hold an advisory committee meeting related to Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene moxeparvovec) marketing application. SRP-9001 is Sarepta's investigational gene therapy for treating Duchenne muscular dystrophy, developed in partnership with Roche Holdings AG (OTC: RHHBY). "This change adds drama to the equation," said Baird analyst Brian Sk
Insider MonkeySarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2022 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon and welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, today’s conference call is being recorded. At this time, I will turn the call over to Mary Jenkins, Associate Director, Investor Relations. Please […]
InvestorPlace7 Biotech Stocks That Will Make You Rich in 10 Years
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news item away from disaster. Further, the smaller enterprises in this exciting arena tend to be extremely unpredictable. Nevertheless, because the sector tends to run on its own fundamentals rather than abiding exclusively by traditional economic metrics, the biotech stocks that wil
Insider MonkeyTop 10 Stock Picks of Eli Casdin’s Casdin Capital
In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […]
Insider Monkey10 Best Pharma Stocks To Buy Now
In this article, we discuss the 10 best pharma stocks to buy now. If you want to see more stocks in this selection, check out the 5 Best Pharma Stocks To Buy Now. With a compound annual growth rate (CAGR) of 9.1%, the global pharmaceuticals industry is projected to expand to $1587.1 billion in 2022 from […]
BenzingaPepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
PepGen Inc (NASDAQ: PEPG) reported data from PGN-EDO51's SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes that PGN-EDO51's safety profile was generally well-tolerated. However, the 15mg/kg dose saw mild hypomagnesemia and an SAE of transient kidney biomarker changes, both events commonly linked to the peptide conjugates that aid oligo delivery. It reiterates its Outperform rating with a price target of $6. On the other hand, the analyst views
BenzingaA Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating. The analyst notes concerns regarding the Phase 3 EMBARK study, with a modest probability of success (60%) for that study. He also acknowledges that the option value associated with an early filing is not yet fully reflected in SRPT. "We see a likely October filing and thus December acceptance as the key catalyst for SRPT into year-end," writes the analyst. The question looms whether the
BenzingaFDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
The FDA has removed the clinical hold on Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-5051 (vesleteplirsen) for Duchenne muscular dystrophy who are amenable to exon 51 skipping. After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expanded monitoring of urine biomarkers. Also Read: Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial. The hold in Part B of Study 5051-201, also known as MOMENTUM, followed a serious a
BenzingaSarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
Sarepta Therapeutics Inc (NASDAQ: SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises. Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy. According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids. Also Read: Sarepta's Duchenne Gene Therapy Up
BenzingaSarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular dystrophy. Last week, the company announced that it would seek accelerated approval for gene therapy. RBC Capital continues to see substantial share appreciation potential even on approval following Phase 3. The potential for accelerated approval provides additional upside optionality to expedite the d
BenzingaDuchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst
Earlier today, Sarepta Therapeutics Inc (NASDAQ: SRPT) announced that it would submit the marketing application and seek accelerated FDA approval for SRP-9001 in Duchenne Muscular Dystrophy (DMD) this fall. Sarepta’s data disclosures earlier this month showed statistically significant functional improvements across company studies compared to an external, matched control, Needham wrote. The analyst increased the price target from $150 to $162, reflecting an increase in expected EPS for 2025. Nee
BenzingaSarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC: RHHBY). Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after treatment compared to a propensity-score weighted external control. Rela
Yahoo財經專欄操盤手札記│一周三單市場奇譚（割柑人）
近期市場波譎雲詭，上周就有幾單奇譚。其一，內地網傳有香港金融機構炒燶債券蝕100億美元，最先傳係外資投行，後來傳係中資大行，再後來傳係中資銀行系券商，係蝕100億元人民幣。